The quest for developing new treatments from imaging techniques: Promises, problems and future potential

Expert Opinion on Drug Discovery

Volumn 2, Issue 8, 2007, Pages 1029-1033

  Minzenberg, Michael J ^a   Carter, Cameron S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; Cognition; Drug development; Functional magnetic resonance imaging; Pharmacology; Psychiatry

Indexed keywords

BIOLOGICAL MARKER; NEUROLEPTIC AGENT;

BRAIN BLOOD FLOW; CLINICAL EFFECTIVENESS; COGNITIVE DEFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; EDITORIAL; ELECTROENCEPHALOGRAPHY; FUNCTIONAL ANATOMY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE DISPLAY; IONIZING RADIATION; LONG TERM MEMORY; MENTAL DISEASE; NEUROIMAGING; NONHUMAN; PHARMACORADIOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA; WORKING MEMORY;

EID: 34548442585     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.8.1029     Document Type: Editorial

References (36)

1. LOPEZ AD, MURRAY CC: The global burden of disease, 1990-2020. Nat. Med (1998) 4(11):1241-1243.
2. AGID Y, BUZSAKI G, DIAMOND DM et al.: How can drug discovery for psychiatric disorders be improved? Nat. Rev. (2007) 6(3):189-201.
3. BAN TA: The role of serendipity in drug discovery. Dial. Clin. Neurosci. (2006) 8(3):335-344.
4. ARGUELLO PA, GOGOS JA: Modeling madness in mice: one piece at a time. Neuron (2006) 52(1):179-196.
5. HAGAN JJ, JONES DN: Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophrenia Bull. (2005) 31(4):830-853.
6. BOWIE CR, HARVEY PD: Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr. Clin. North Am. (2005) 28(3):613-633.
7. GREEN MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry (1996) 153(3):321-330.
8. RAGLAND JD, YOON J, MINZENBERG MJ, CARTER CS: Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological model. Intern. Rev. Psychiatry (In Press).
9. CARTER CS: Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia. Schizophrenia Bull. (2005) 31(4):810-815.
10. SHARMA T, ANTONOVA L: Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr. Clin. North Am. (2003) 26(1):25-40.
11. MCGURK SR, MUESER KT: Cognitive functioning, symptoms, and work in supported employment: a review and heuristic model. Schizophrenia Res. (2004) 70(2-3):147-173.
12. GREEN MF, KERN RS, HEATON RK: Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophrenia Res. (2004) 72(1):41-51.
13. MIYAMOTO S, DUNCAN GE, MARX CE, LIEBERMAN JA: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry (2005) 10(1):79-104.
14. BREIER A: Developing drugs for cognitive impairment in schizophrenia. Schizophrenia Bull. (2005) 31(4):816-822.
15. GARDNER DM, BALDESSARINI RJ, WARAICH P: Modern antipsychotic drugs: a critical overview. CMAJ (2005) 172(13): 1703-1711.
16. HARVEY PD, KEEFE RS: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry (2001) 158(2):176-184.
17. CARPENTER WT, GOLD JM: Another view of therapy for cognition in schizophrenia. Biol. Psychiatry (2002) 51(12):969-971.
18. STIP E, CHOUINARD S, BOULAY LJ: On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog. Neuro Psychopharmacol. Biol. Psychiatry (2005) 29(2):219-232.
19. WEISS EM, BILDER RM, FLEISCHHACKER WW: The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (2002) 162(1):11-17.
20. LESLIE RA, JAMES MF: Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol. Sci. (2000) 21(8):314-318.
21. HONEY G, BULLMORE E: Human pharmacotogical MRI. Trends Pharmacol. Sci. (2004) 25(7):366-374.
22. BORSOOK D, BECERRA L, HARGREAVES R: A role for fMRI in optimizing CNS drug development. Nat. Rev. (2006) 5(5):411-424.
23. LOGOTHETIS NK, WANDELL BA: Interpreting the BOLD signal. Ann. Rev. Physiol. (2004) 66:735-769.
24. NORRIS DG: Principles of magnetic resonance assessment of brain function. J. Magn. Reson. Imaging (2006) 23(6):794-807.
25. STEIN EA: fMRI: a new tool for the in vivo localization of drug actions in the brain. J. Anal. Toxicol. (2001) 25(5):419-424.
26. HONEY GD, BULLMORE ET, SONI W et al.: Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc. Natl. Acad. Sci. USA (1999) 96(23):13432-13437.
27. HONEY GD, SUCKLING J, ZELAYA F et al.: Dopaminergic drug effects on physiological connectivity in a human cortico-striato-thalamic system. Brain (2003) 126(Part 8):1767-1781.
28. STEPHAN KE, MAGNOTTA VA, WHITE T et al.: Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task. Psychol. Med. (2001) 31(6):1065-1078.
29. CHEN YC, GALPERN WR, BROWNELL AL et al.: Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn. Reson. Med. (1997) 38(3):389-398.
30. CHEN YI, BROWNELL AL, GALPERN W et al.: Detection of dopaminergic cell loss and neural transplantation using pharmacological MRI, PET and behavioral assessment. Neuroreport (1999) 10(14):2881-2886.
31. NOLL DC, GENOVESE CR, NYSTROM LE et al.: Estimating test-retest reliability in functional MR imaging. II. Application to motor and cognitive activation studies. Magn. Reson. Med. (1997) 38(3):508-517.
32. WISE RG, TRACEY I: The role of fMRI in drug discovery. J. Magn. Reson. Imaging (2006) 23(6):862-876.
33. HANDWERKER DA, OLLINGER JM, D'ESPOSITO M: Variation of BOLD hemodynamic responses across subjects and brain regions and their effects on statistical analyses. Neuroimage (2004) 21(4):1639-1651.
34. WONG EC: Quantifying CBF with pulsed ASL: technical and pulse sequence factors. J. Magn. Reson. Imaging (2005) 22(6):727-731.
35. GOLLUB RL, BREITER HC, KANTOR H et al.: Cocaine decreases cortical cerebral blood flow but does not obscure regional activation in functional magnetic resonance imaging in human subjects. J. Cereb. Blood Flow Metab. (1998) 18(7):724-734.
36. CHO RY, FORD JM, KRYSTAL JH et al.: Functional neuroimaging and electrophysiology biomarkers for clinical trials for cognition in schizophrenia. Schizophrenia Bull. (2005) 31(4):865-869.